(Q36583570)

15 August 2017

1 reference

title

Novel approaches in the treatment of systemic mastocytosis (English)

1 reference

15 August 2017

5

Hagop Kantarjian

1 reference

15 August 2017

6

Srdan Verstovsek

1 reference

15 August 2017

3

Jorge Cortes

1 reference

PubMed ID

16948123

15 August 2017

Alfonso Quintas-Cardama

series ordinal

1

object named as

Alfonso Quintas-Cardama

1 reference

15 August 2017

4

Francis J Giles

1 reference

15 August 2017

Ahmed Aribi

2

1 reference

PubMed ID

16948123

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

107

1 reference

15 August 2017

7

1 reference

15 August 2017

1429-1439

1 reference

Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.

15 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

Mastocytosis: pathology, genetics, and current options for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Systemic mastocytosis: bone marrow pathology, classification, and current therapies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Diagnostic criteria and classification of mastocytosis: a consensus proposal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Normal and oncogenic forms of the receptor tyrosine kinase kit.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Structure of a c-kit product complex reveals the basis for kinase transactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Multilineage hematopoietic involvement in systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Cytogenetic studies in patients with mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Treatment of systemic mast cell disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Diagnosis and treatment of systemic mastocytosis: state of the art.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Clinical, genetic, and therapeutic insights into systemic mast cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

A new c-kit mutation in a case of aggressive mast cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

A germline mutation in KIT in familial diffuse cutaneous mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Mastocytosis: current treatment concepts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Temporal quantitation of mutant Kit tyrosine kinase signaling attenuated by a novel thiophene kinase inhibitor OSI-930.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Hsp90 inhibitors as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

NF-kappaB and cell-cycle regulation: the cyclin connection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22187

7 January 2021

Identifiers

DOI

10.1002/CNCR.22187

1 reference

15 August 2017

1 reference

PubMed ID

16948123